Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 18, Issue 8, Pages -Publisher
SPRINGER
DOI: 10.1007/s11910-018-0852-4
Keywords
Congenital myasthenic syndromes; Neuromuscular junction; EMG; Mutation analysis; Expression studies
Categories
Funding
- NIH [NS6277]
Ask authors/readers for more resources
Purpose of Review Summarize features of the currently recognized congenital myasthenic syndromes (CMS) with emphasis on novel findings identified in the past 6 years. Since the last review of the CMS in this journal in 2012, several novel CMS were identified. The identified disease proteins are SNAP25B, synaptotagmin 2, Munc13-1, synaptobrevin-1, GFPT1, DPAGT1, ALG2, ALG14, Agrin, GMPPB, LRP4, myosin 9A, collagen 13A1, the mitochondrial citrate carrier, PREPL, LAMA5, the vesicular ACh transporter, and the high-affinity presynaptic choline transporter. Exome sequencing has provided a powerful tool for identifying novel CMS. Identifying the disease genes is essential for determining optimal therapy. The landscape of the CMS is still unfolding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available